The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

The U.S. Food and Drug Administration and the European Medicines Agency jointly issued principles for safe and responsible ...

NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to ...

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...

Accelerated drug discovery and development platform Converge Bio Inc. today announced it has raised $25 million in ...

At the J.P. Morgan Healthcare Conference, Nvidia announced major AI partnerships with Lilly and Thermo Fisher Scientific to ...

The San Diego firm took a step in that direction on Tuesday, when it unveiled what it says will be the world’s largest ...

Nvidia and Eli Lilly and Co. are partnering to create an artificial intelligence lab in the San Francisco Bay Area to ...

Converge Bio, the AI platform for accelerated drug discovery and development, announced today $25 million in Series A funding ...

Converge Bio CEO Dov Gertz said, "The conversation needs to shift from models to AI systems. Unlike ChatGPT, you can’t simply ...